Cost-Reduction Becoming a Top Priority for Domestic Drug Makers Due to Sluggish Sales of Long-Listed Drugs, Impact of NHI Pricing System Reform

Domestic drug makers have announced their settlements of accounts for the fiscal year ended March 2014. Generic drugs continued to advance in the market, resulting in a bigger-than-expected decline in sales of long-listed drugs. In overseas markets, however, a number...read more